68 Ga-pentixafor PET/CT versus adrenal venous sampling in guiding surgical management for primary aldosteronism: a prospective cohort study on postoperative outcomes.

BACKGROUND

Limitations still exist in the surgical strategies for primary aldosteronism (PA), the most common cause of secondary hypertension. This study aimed to compare the effectiveness of 68 Ga-pentixafor PET/CT versus adrenal venous sampling (AVS) in guiding surgical management for PA.

MATERIALS AND

METHODS

A prospective cohort of 197 PA patients were assigned to Group PET (n = 137) and Group AVS (n = 60), in which the surgical interventions were guided by 68 Ga-pentixafor PET/CT and AVS, respectively. Postoperative clinical and biochemical outcomes were analyzed referring to Primary Aldosteronism Surgical Outcomes classification system, with subgroup analysis on clinical characteristics and outcomes conducted in Group PET.

RESULTS

During a median follow-up of 27 (16, 39) months, the postoperative clinical and biochemical outcomes were comparable between 134 patients in Group PET and 57 patients in Group AVS, with unilateral or bilateral adrenal lesions. The rates of complete, partial, and absent clinical success were 51.5%, 38.1%, 10.4% in Group PET, and 35.1%, 50.9%, 14.0% in Group AVS ( P = 0.115). For biochemical success, the corresponding rates were 82.1%, 12.7%, 5.2% in Group PET, and 75.4%, 17.5%, 7.0% in Group AVS ( P = 0.533). The proportion of complete biochemical success was significantly higher than that of complete clinical success (80.10% vs 46.6%, P < 0.001). Female gender was associated with increased likelihood of complete clinical and biochemical success, and lower preoperative systolic blood pressure and shorter duration of hypertension indicated increased likelihood of complete clinical success. The SUV max was significantly correlated with lesion diameters, age, duration of hypertension, blood potassium level, pathological type and clinical outcomes. A cutoff value of 5.5 for SUV max demonstrated a sensitivity of 82.8% and a specificity of 92.6% in identifying functional adrenal lesions with autonomous aldosterone secretion.

CONCLUSIONS

68 Ga-pentixafor PET/CT demonstrated potential non-inferiority to AVS in guiding the surgical management for PA patients, with comparable postoperative clinical and biochemical outcomes.